21/10/2025 06:30
EQS-News: Formycon’s FYB201/Ranivisio® sets innovative standard as Europe’s First Ranibizumab Biosimilar available in Pre-filled Syringe
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Formycon AG / Key words: Market Launch/Product Launch br/ Formycon’s FYB201/Ranivisio® sets innovative standard as Europe’s First Ranibizumab Biosimilar available in... Lire...
16/10/2025 06:30
EQS-News: Actor Pharmaceuticals and Megalabs become partners for the commercialization of Formycon’s Eylea® biosimilar FYB203 (aflibercept) for Australia and Latin America
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Formycon AG / Key words: Agreement br/ Actor Pharmaceuticals and Megalabs become partners for the commercialization of Formycon’s Eylea® biosimilar FYB203 aflibercept for... Lire...
02/10/2025 06:30
EQS-News: Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Formycon AG / Key words: Market Launch/Agreement br/ Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with... Lire...
17/09/2025 15:55
Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
html xmlns=http://www.w3.org/1999/xhtmlbodytable border=trtd p OriginalResearch: Formycon AG from First Berlin Equity Research GmbH br/br/ 17.09.2025 / 15:55 CET/CESTbr/ Dissemination of a Research, transmitted by EQS News a service of EQS Group.br/ The issuer is solely responsible for... Lire...
17/09/2025 06:30
EQS-News: Horus Pharma becomes additional commercialization partner for Formycon's Eylea® biosimilar FYB203 in selected European countries under the brand name Baiama®
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Formycon AG / Key words: Agreement br/ Horus Pharma becomes additional commercialization partner for Formycons Eylea® biosimilar FYB203 in selected European countries under the... Lire...
13/08/2025 06:30
EQS-News: Formycon confirms full-year guidance following business development in line with plan – working capital raised
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Formycon AG / Key words: Half Year Results/Half Year Report br/ Formycon confirms fullyear guidance following business development in line with plan – working capital raised... Lire...
04/08/2025 11:45
Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
html xmlns=http://www.w3.org/1999/xhtmlbodytable border=trtd p OriginalResearch: Formycon AG from First Berlin Equity Research GmbH br/br/ 04.08.2025 / 11:45 CET/CESTbr/ Dissemination of a Research, transmitted by EQS News a service of EQS Group.br/ The issuer is solely responsible for... Lire...
30/07/2025 06:30
EQS-News: Formycon invites to conference call on 2025 half-year results and announces participation in international investor conferences in the 3rd quarter of 2025
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Formycon AG / Key words: Miscellaneous br/ Formycon invites to conference call on 2025 halfyear results and announces participation in international investor conferences in the 3rd... Lire...
10/07/2025 06:30
EQS-News: Formycon successfully completes patient enrollment for the clinical development of its Keytruda® biosimilar candidate FYB206
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Formycon AG / Key words: Study br/ Formycon successfully completes patient enrollment for the clinical development of its Keytruda® biosimilar candidate FYB206... Lire...